



Republic of the Philippines
PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City
Healthline 637-9999 www.philhealth.gov.ph



PHILHEALTH CIRCULAR

No. 08, s-2005

TO

**: ALL ACCREDITED HEALTH CARE PROVIDERS,
PHILHEALTH MEMBERS, AND ALL OTHERS
CONCERNED**

SUBJECT


**: Newly listed drugs and drug preparations in the PNDF
Volume One, Sixth Edition- Sections 9, 10, 11 and 12**

The National Formulary Committee of the Department of Health has released the official list of drugs under the following sections: 9.0 Antineoplastics and Immunosuppressants, 10.0 Drugs Affecting the Blood, 11.0 Blood Products and Blood Substitutes, and 12.0 Antidotes of the latest edition of the Philippine National Drug Formulary (PNDF) Volume One (1), Sixth (6th) edition, as approved by the Secretary of Health.

Pursuant to Section 37 of Republic Act 7875 and PhilHealth Board Resolution No. 265 s. 1999 which provides for the use of the latest edition of the PNDF for reimbursement, the said list of drugs shall be implemented as follows:

1. Newly listed drugs and drug preparations that are now included in Sections 9.0, 10.0, 11.0, and 12.0 of the PNDF, Volume 1, 6th edition (Annexes 1-4), **shall be compensable for claims with discharge dates starting March 1, 2005.**
2. Denial of PhilHealth coverage or reimbursement of delisted drugs and drug preparations for the above mentioned sections of the PNDF shall be held in abeyance pending the completion of the entire PNDF list or provision of reasons for the deletion of the same by the National Formulary Committee.

All other issuances inconsistent with this circular are hereby repealed and modified accordingly.


Francisco T. Duque III
Secretary
President and CEO

Date: 2/21/05

ANNEX 1

NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDF VOL. ONE (1) SIXTH (6TH) EDITION

Section 9.0 ANTINEOPLASTICS AND IMMUNOSUPPRESSANTS

A. NEWLY LISTED DRUGS (compensable by March 1, 2005)

GENERIC NAME	ROUTE	PREPARATION
Basiliximab (1,2)	Inj.:	20 mg vial (IV Infusion)
▼ Doxetacel (1,2)	Inj.:	20 mg/0.5 mL, 0.5 mL vial (IV Infusion) (anhydrous) 40 mg/mL, 2 mL vial (IV Infusion) (anhydrous)
▼ Gemcitabine (1, 2)	Inj.:	200 mg vial (IV Infusion) (as hydrochloride) 1 g vial (IV Infusion) (as hydrochloride)
▼ Irinotecan (1, 2)	Inj.:	40 mg/2 mL concentrate, vial (IV Infusion) (as hydrochloride) 100 mg/5 mL concentrate, vial (IV Infusion) (as hydrochloride)
Paclitaxel (1,2)	Inj.:	6 mg/mL, 5 mL, 17 mL, 25 mL and 43.4 mL vial (IV, IV Infusion) 100 mg/15 mL, 15 mL multidose vial (IV) powder, 100 mg vial (IV) powder, 260 mg vial (IV)
▼ Sirolimus	Oral:	1 mg tablet 1 mg/mL solution, 60 mL
▼ Tacrolimus	Oral:	1 mg and 5 mg capsule
	Inj.:	5 mg/mL, 1 mL ampul (concentrate) (IM, IV Infusion)

-Nothing follows-

B. NEWLY LISTED DRUG PREPARATIONS (compensable by March 1, 2005)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
▼ Calcium folinate (1,2) (leucovorin calcium)	Oral:	15 mg capsule and 25 mg tablet (as anhydrous) (equiv. to 25 mg folic acid) 3 mg/mL, 1 mL ampul (IM, IV) 10 mg/mL, 5 mL vial (IM, IV) 10 mg/mL, 10 mL ampul/vial (IM, IV) 15 mg/mL, 1 mL ampul (IM, IV) 100 mg and 340 mg vial (IM, IV)
Carboplatin (1,2)	Inj.:	10 mg/mL, 50 mL vial (IV)
Cisplatin (1,2)	Inj.:	1 mg/mL, 20 mL vial (IV)
Cytarabine (1,2)	Inj.:	50 mg/mL, 10 mL vial (IV Infusion)
Etoposide (1,2)	Inj.:	20 mg/mL, 2.5 mL and 10 mL vial powder, 100 mg vial (IV)
Fluorouracil (1,2)	Inj.:	25 mg/mL, 10 mL vial (IV, IV Infusion) 50 mg/mL, 20 mL and 100 mL ampul/vial (IV, IV Infusion)
Interferon alfa 2a (human) (1,2)	Inj.:	3 million IU, pre-filled syringe (IM, SC) 4.5 million IU/0.5 mL pre-filled syringe (SC) 6 million IU/0.5 mL pre-filled syringe (SC) 9 million IU/0.5 mL pre-filled syringe (SC, IM)

B. NEWLY LISTED DRUG PREPARATIONS (compensable by March 1, 2005)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
Leuproreline (1,2)	Inj.:	powder (depot), 11.25 mg vial with syringe (IM, SC) (as acetate) powder, 1.88 mg vial with syringe (IM, SC) (as acetate)
Mesna (1,2) (sodium-2-mercapto ethanesulphonate)	Inj.:	100 mg/mL, 5 mL and 10 mL ampul (IV)
Methotrexate	Oral:	5 mg tablet (as sodium salt) (B)
	Inj.:	10 mg/mL, 1 mL and 5 mL vial (IM) (as sodium salt) 100 mg/mL, 5 mL, 10 mL and 50 mL vial (IM, IV, Intrathecal) (as sodium salt, preservative- free)
Mitoxantrone (1,2)	Inj.:	2 mg/mL solution, 5 mL (IV) (as hydrochloride)
Mycophenolate (1,2) mofetil	Oral:	500 mg tablet
Tamoxifen (1,2)	Oral:	30 mg and 40 mg tablet (as citrate)

-Nothing follows-

ANNEX 2

NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDF VOL. ONE (1) SIXTH (6TH) EDITION

Section 10.0 DRUGS AFFECTING THE BLOOD

A. NEWLY LISTED DRUGS (compensable by March 1, 2005)

CATEGORY	ROUTE	PREPARATION
▼ Clopidogrel	Oral:	75 mg tablet
Epoetin beta (1,2) (recombinant erythropoietin)	Inj.:	2,000 IU/0.3 mL, pre-filled syringe with needle (IV, SC) 4,000 IU/0.3 mL, pre-filled syringe with needle (IV, SC) 5,000 IU/0.3 mL, pre-filled syringe with needle (IV, SC) lyophilized powder, 1,000 IU vial + solvent ampul (IV, SC) lyophilized powder, 10,000 IU vial + solvent ampul (IV, SC)
★ Recombinant tissue plasminogen activator (rTPA) (1,2)	Inj.:	1 mg/mL, 50 mL vial (IV Infusion)

-Nothing follows-

B. NEWLY LISTED DRUG PREPARATIONS (compensable by March 1, 2005)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
Epoetin alfa (1,2) (recombinant human erythropoietin)	Inj.:	▼ 2,000 IU/0.2 mL, pre-filled syringe (IV)
Dalteparin (1,2)	Inj.:	10,000 IU/mL, 1 mL ampul (SC) (as sodium)
▼ Enoxaparin (1,2)	Inj.:	100 mg/mL, 1 mL vial (SC) (as sodium) 2,000 IU (20 mg)/0.2 mL, 4,000 IU (40 mg)/0.4 mL, 6,000 IU (60 mg)/0.6 mL and 8,000 IU (80 mg)/0.8 mL pre-filled syringe (SC)
Filgrastim (1,2) (G-CSF)	Inj.:	150 mcg/0.6 mL, vial (IV, SC) 300 mcg/1.2 mL, vial (IV, SC)
Streptokinase (1)	Inj.:	powder, 750,000 IU vial (IV Infusion)

-Nothing follows-

ANNEX 3

NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDF VOL. ONE (1) SIXTH (6TH) EDITION

Section 11.0 BLOOD PRODUCTS AND BLOOD SUBSTITUTES

A. NEWLY LISTED DRUGS (compensable by March 1, 2005)

CATEGORY	ROUTE	PREPARATION
Modified fluid gelatin (polymerisate of degraded succinylated gelatin)	Inj.:	3% and 4% solution, 500 mL bottle (IV Infusion)

-Nothing follows-

B. NEWLY LISTED DRUG PREPARATIONS (compensable by March 1, 2005)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
Hydroxyethyl starch	Inj.:	6% solution, 250 mL bottle (IV Infusion) 10% solution, 250 mL bottle (IV Infusion)
Factor IX complex concentrate (1,2) (coagulation factors II, VII, IX, X)	Inj.:	100 IU/mL, 5 mL and 10 mL vial (IV)

-Nothing follows-

ANNEX 4

NEW DRUGS AND DRUG PREPARATIONS INCLUDED IN THE PNDF VOL. ONE (1) SIXTH (6TH) EDITION

Section 12.0 ANTIDOTES

A. NEWLY LISTED DRUGS (compensable by March 1, 2005)

CATEGORY	ROUTE	PREPARATION
Bromocriptine (neuroleptic malignant syndrome)	Oral:	2.5 mg tablet (as mesilate)
Dimercaptopropane-sulphonate (DMPS) (for arsenic and methyl mercury poisoning)	Inj.:	100 mg/mL, 1 mL ampul, 10 mL vial (IM)
Lorazepam (for drug-induced seizures)	Inj.:	4 mg/mL, 1 mL ampul (IM,IV) (Also listed under Section 1.0 Drugs Acting on the Nervous System)
★ Methylene blue (for severe methemoglobinemia)	Oral:	1% solution 55 mg and 65 mg tablet
	Inj.:	10 mg/mL, 1 mL and 10 mL ampul/vial (IV)
Naltrexone (for narcotic addiction and alcoholism)	Oral:	50 mg tablet (as hydrochloride)

-Nothing follows-

B. NEWLY LISTED DRUG PREPARATIONS (compensable by March 1, 2005)

Note: The following drugs, in their generic/international non-proprietary names (INN), are already included in the 5th edition of the PNDF. Below are the newly listed preparations of these drugs as contained in the 6th (latest) edition of the PNDF.

GENERIC NAME	ROUTE	PREPARATION
Calcium folinate (leucovorin calcium for drug-induced megaloblastic anemia, formaldehyde and methyl alcohol poisoning and methotrexate toxicity)	Oral:	15 mg capsule and 25 mg tablet (as anhydrous) (equiv. to 25 mg folic acid)
	Inj.:	3 mg/mL, 1 mL ampul (IM, IV)
		10 mg/mL, 10 mL vial (IM, IV)
		15 mg/mL, 1 mL ampul (IM, IV) 340 mg vial (IM, IV, IV infusion)
Deferoxamine (1) (for iron poisoning)	Inj.:	powder, 2 g vial (IM, IV, SC) (as mesilate)
Flumazenil (for benzodiazepine poisoning)	Inj.:	100 mcg/mL, 10 mL ampul (slow IV, IV infusion)
Pyridoxine (Vitamin B6) (for isoniazid poisoning, hydrogen sulfide poisoning, gynomethrin mushroom poisoning and theophylline poisoning)	Inj.:	100 mg/mL, 10 mL ampul (IM, IV) (as hydrochloride)
★ Sodium nitrite (for cyanide poisoning)	Inj.:	30 mg/mL, 10 mL ampul (IV)

-Nothing follows-